Vigil Neuroscience, Inc. (NASDAQ:VIGL) Receives Average Rating of "Hold" from Analysts

Vigil Neuroscience, Inc. (NASDAQ:VIGL - Get Free Report) has been given a consensus recommendation of "Hold" by the ten analysts that are currently covering the stock, MarketBeat.com reports. Ten investment analysts have rated the stock with a hold recommendation. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $10.80.

A number of equities research analysts recently weighed in on VIGL shares. Stifel Nicolaus cut shares of Vigil Neuroscience from a "buy" rating to a "hold" rating and cut their price objective for the company from $11.00 to $8.00 in a research note on Wednesday, May 28th. Jefferies Financial Group cut shares of Vigil Neuroscience to a "hold" rating in a research note on Thursday, May 22nd. HC Wainwright cut shares of Vigil Neuroscience from a "buy" rating to a "neutral" rating and cut their price objective for the company from $14.00 to $8.00 in a research note on Tuesday, May 27th. JMP Securities restated a "market perform" rating on shares of Vigil Neuroscience in a research note on Thursday, May 22nd. Finally, Wedbush cut shares of Vigil Neuroscience from a "strong-buy" rating to a "hold" rating and cut their price objective for the company from $13.00 to $8.00 in a research note on Thursday, May 22nd.

Vigil Neuroscience Price Performance

Shares of NASDAQ VIGL traded up $0.04 during mid-day trading on Tuesday, hitting $7.92. The company had a trading volume of 2,800,869 shares, compared to its average volume of 739,353. The stock has a market cap of $369.63 million, a price-to-earnings ratio of -3.86 and a beta of 3.43. Vigil Neuroscience has a 12 month low of $1.31 and a 12 month high of $7.95. The firm's 50 day simple moving average is $4.29 and its two-hundred day simple moving average is $2.86.

Vigil Neuroscience (NASDAQ:VIGL - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The company reported ($0.49) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.53) by $0.04. Equities analysts forecast that Vigil Neuroscience will post -2.07 earnings per share for the current year.

Institutional Investors Weigh In On Vigil Neuroscience

Hedge funds and other institutional investors have recently bought and sold shares of the business. Cubist Systematic Strategies LLC raised its position in Vigil Neuroscience by 53.0% in the fourth quarter. Cubist Systematic Strategies LLC now owns 24,120 shares of the company's stock worth $41,000 after acquiring an additional 8,358 shares in the last quarter. Squarepoint Ops LLC acquired a new stake in Vigil Neuroscience during the 4th quarter worth about $193,000. Barclays PLC raised its holdings in Vigil Neuroscience by 43.6% during the 4th quarter. Barclays PLC now owns 64,049 shares of the company's stock worth $109,000 after buying an additional 19,436 shares during the period. Jane Street Group LLC acquired a new stake in Vigil Neuroscience during the 4th quarter worth about $83,000. Finally, Millennium Management LLC raised its holdings in Vigil Neuroscience by 23.3% during the 4th quarter. Millennium Management LLC now owns 343,814 shares of the company's stock worth $584,000 after buying an additional 65,058 shares during the period. 83.64% of the stock is currently owned by institutional investors.

About Vigil Neuroscience

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.